Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
Durvalumab safely improves survival in lung cancer patients with limited physical function Dr. Kamal Kant Kohli1 Dec 2023 9:00 AM ISTUSA: A recent study published in eClinicalMedicine has shown single-agent durvalumab to be safe and well tolerated in the first-line treatment of...
Janssen seeks USFDA nod for Rybrevant plus chemotherapy for patients with EGFR-Mutated Non-Small Cell Lung Cancer who progressed on or after Osimertinib Ruchika Sharma23 Nov 2023 2:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License ...
USFDA nod to Bristol Myers Squibb Augtyro for lung cancer Ruchika Sharma16 Nov 2023 5:30 PM ISTAugtyro is designed to minimize interactions that can lead to certain forms of treatment resistance in ROS1-positive metastatic NSCLC patients.
Intas Pharma to commercialise Serplulimab in India Ruchika Sharma30 Oct 2023 3:29 PM ISTSerplulimab will be commercialised by Intas in India and by its subsidiary, Accord Healthcare Ltd, in Europe.
AstraZeneca-Daiichi Sankyo Enhertu approved in EU for lung cancer Ruchika Sharma24 Oct 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the...
Medical Bulletin 19/October/2023 Roshni Dhar19 Oct 2023 3:15 PM ISTLung cancer treatment research enters a new eraAdvances in lung cancer treatment highlight importance of tumour testing at diagnosisResearch presented...
Lung cancer treatment research enters a new era Roshni Dhar19 Oct 2023 9:00 AM ISTAdvances in lung cancer treatment highlight importance of tumour testing at diagnosisResearch presented at the ESMO Congress 2023 sets potential major...
European Commission nod to Merck Keytruda for non-small cell lung cancer at high risk of recurrence Ruchika Sharma17 Oct 2023 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Commission (EC) has approved KEYTRUDA,...
AstraZeneca gets USFDA priority review for Tagrisso plus chemotherapy for EGFR-mutated advanced lung cancer Ruchika Sharma17 Oct 2023 2:24 PM ISTCambridge: AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and...
Merck gets USFDA nod for neoadjuvant/ adjuvant Keytruda for resectable non-small cell lung cancer Ruchika Sharma17 Oct 2023 12:54 PM ISTThe approval marks the sixth NSCLC indication for KEYTRUDA.
Metabolic Syndrome Linked to Increased Lung Cancer Risk Jacinthlyn Sylvia17 Oct 2023 6:15 AM ISTIn a recent study conducted within the UK Biobank, Mengmeng Li and team unveiled a significant association between Metabolic Syndrome (MetS) and an...
